Tumentia Research
Casper
About Tumentia Research
Tumentia is a pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded by graduates of the Concordia University in Montreal, Canada & the University of Wyoming in 2014. We develop novel therapies for cancer patients. Our research has resulted in five pre-clinical stage drugs that treat different types of cancers. Tumentia has been acquired by Excellence Health Inc. in October, 2017 & will now operate as a subsidiary.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $60.0M
- Funding stage: M&A
- Last round: Series A (Jan 2015)
- Website: tumentia.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/tumentia-research-2153745 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.